The Russian medicine product Longidaza® has received a patent which is valid on the territory of the Republic of India
The Russian pharmaceutical company Petrovax has received a patent for the original medicine product Longidaza®, which is valid in India1 protecting its exclusive right to the medicinal product for 20 years. Thus, Longidaza® enters the markets of the BRICS countries2, in this way continuing to win worldwide recognition.
Longidaza® is used for treatment and prevention of diseases accompanied by the formation of adhesions and various types of fibrosis (pulmonary fibrosis, prostate fibrosis, etc.)3. Longidaza® has a multicomponent action and is well- proven in combined therapy and in monotherapy of various diseases associated with inflammation and hyperplasia of the connective tissue (fibrosis, adhesions)4. During the COVID-19 pandemic, the drug product helps to cope with post-COVID consequences accompanied by impaired lung function. Shortness of breath is one of the most common symptoms that can persist for a long time after infection and represents a manifestation of inflammatory changes in the lungs of patients who had COVID-19. In 2020–2021, Petrovax conducted an additional study to assess the efficacy and safety of Longidaza®. It showed good results in the treatment of patients who had COVID-19. Those patients made good progress and recovered faster from the disease.
Entering the Indian market is another step that continues the geographical expansion of the drug product. In 2015, WHO (World Health Organization) recognized the originality of the Longidaza®5 molecule by assigning the international non-proprietary name (INN) bovhyarulonidase azoximer to it. In 2021, the drug product has received a European patent, which is valid in the UK, Germany, France, Switzerland, Ireland and Belgium. In 2021, sales of the drug product in Russia and worldwide exceeded 1.7 million packs. Out of these numbers the share of export supplies of the drug product was 9%.
The market of the BRICS countries has great potential for the use of drug products from the Longidaza® group. In India alone, according to preliminary estimates, there are about 130 thousand patients diagnosed with idiopathic pulmonary fibrosis6. According to other data, in large countries such as Brazil, Russia, India and China (the BRICS region), this parameter is close to 2 million people in total7.
1 Indian Patent № 385717 for the following invention: METHOD FOR PRODUCING HYALURONIDASE CONJUGATE WITH POLYETHYLENEPIPERAZINE DERIVATIVES AND THE USE OF THE CONJUGATE PRODUCED.
2 An interstate group comprising of the Federative Republic of Brazil, the Russian Federation, the Republic of India, the People’s Republic of China and the Republic of South Africa, established in June 2006 on the initiative of the Russian side.
3 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5b2f46a3-77d6-43af-a5d9-ccdffe6e14d6&t=
4 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5b2f46a3-77d6-43af-a5d9-ccdffe6e14d6&t=
5 https://www.who.int/medicines/publications/druginformation/issues/74_INN_List.pdf
6 Источник: Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015 Sep 24;13:237. doi: 10.1186/s12916-015-0495-0. Erratum in: BMC Med. 2021 Sep 5;19(1):220. PMID: 26399999; PMCID: PMC4581420. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581420/
7 Источник: Rivera-Ortega, P. and Molina-Molina, M., 2019. Interstitial Lung Diseases in Developing Countries. Annals of Global Health, 85(1), p.4. DOI: https://annalsofglobalhealth.org/articles/10.5334/aogh.2414/
